SHINE Technologies LLC has secured an additional $70 million in funding from current stakeholders Baillie Gifford and Fidelity Management & Research Company, and new institutional investors. This investment will support SHINE's fusion strategy and expedite the domestic production of medical isotopes, aligning with the company's long-term goal of providing cost-effective fusion energy.